Form 4 holding
Director
Spyre Therapeutics, Inc.
- Security class
- Stock Option (Right to Buy)
- Shares / value
- 25,000
- Estimated value
- Report date
- 29 May 2025
- Price
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount